Pfizer (PFE) Income from Non-Controlling Interests (2009 - 2026)

Pfizer has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting $8.0 million for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 33.33% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $43.0 million (up 48.28% YoY), while the FY2025 annual figure was $41.0 million, up 32.26% from the prior year.
• Income from Non-Controlling Interests held at $8.0 million in Q1 2026, from $8.0 million in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for PFE reached as high as $18.0 million in Q2 2025 and fell as low as $6.0 million in Q2 2022.
• The 5-year median for Income from Non-Controlling Interests is $8.0 million (2024), against an average of $9.2 million.
• Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests tumbled 76.92% — and 2025, when it jumped 157.14%.
• A 5-year view of Income from Non-Controlling Interests shows it stood at $15.0 million in 2022, then slumped by 40.0% to $9.0 million in 2023, then fell by 11.11% to $8.0 million in 2024, then changed by 0.0% to $8.0 million in 2025, then changed by 0.0% to $8.0 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $8.0 million, $8.0 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.